Baxter's Global Portfolio:


Emulsion for Infusion

Numeta is approved in select countries outside the U.S.; it is not approved/cleared in the U.S.


Meet NUMETA: The Triple-Chamber, Ready-To-Use IV Nutrition System for Preterm Newborns and Children

NUMETA is the first ready-to-use parenteral (intravenous) nutrition (PN) product available to treat preterm neonates and pediatric patients who have acute nutritional requirements by providing a formulation of amino acids (protein), glucose (carbohydrates), lipids (fats) and electrolytes in a triple-chamber system pioneered by Baxter.

Product Details

  • NUMETA is offered in multiple formulations specifically developed for pediatric patients in different growth stages including NUMETA G13E 300mL, which is the only ready-to-use PN product available for preterm infants.
  • Additional NUMETA formulations include NUMETA G16E 500mL for full term infants through two years of age, and NUMETA G19E 1,000mL for children and adolescents (2-18 years of age).
  • NUMETA’s design also allows for activation and administration at bedside.
  • NUMETA is available in select European and Latin American countries. For prescribing information, please visit us at


# About Baxter /sites/baxter/inside-baxter/about/overview/ Corporate Overview /baxter/inside-baxter/about/overview/ Science & Innovation /baxter/inside-baxter/science/innovations/ Careers /baxter/ Investors Corporate Responsibility /baxter/ News & Media /baxter/ Our Products & Expertise /baxter/ Overview /baxter/products-expertise/ Acute Therapies /baxter/products-expertise/renal-failure-treatments/ Dialysis /baxter/products-expertise/renal-failure-treatments/ IV/Infusion /baxter/products-expertise/iv-infusion-systems/ Nutrition /baxter/products-expertise/parenteral-nutrition/ Surgery /baxter/products-expertise/advanced-surgery/ Contract Manufacturing /baxter/products-expertise/ Material Safety Data Sheet Authorized Distributor of Record /assets/downloads/2015/Baxter - ADR List Jun 11 2015.pdf Contact & Support /baxter/contact-and-support/ Contact /baxter/contact-and-support/ Product Catalog eServices Center Sitemap /baxter/ Privacy at Baxter /baxter/ Copyright & Legal Disclaimers /baxter/ Linking Disclaimers /baxter/ Web Accommodations /baxter/ Cybersecurity /baxter/ linkedin LinkedIn twitter Twitter facebook Facebook youtube YouTube rss RSS /baxter/news-media/newsroom/ email email 2017
USMP/81/17-0008 true Keep up with Baxter [$WSSP] = [443] [$WSCS] = [TLS_ECDHE_RSA_WITH_AES_128_CBC_SHA-128] [Host] = [] [$WSSN] = [] [User-Agent] = [Mozilla/5.0 (Macintosh; Intel Mac OS X 10_10_1) AppleWebKit/600.1.25 (KHTML, like Gecko) Version/8.0 Safari/600.1.25] [$WSSI] = [YnpJMWtHOG9zRjdTbi9LUElJMC9UU1dUNTMzelgrOWoxR0VNcnQ3YjY0UT0=] [$WSSC] = [https] [$WSRH] = [] [$WSIS] = [true] [Surrogate-Capability] = [WS-ESI="ESI/1.0+"] [$WSRA] = [] [_WS_HAPRT_WLMVERSION] = [-1] [Accept-Encoding] = [gzip] [$WSPR] = [HTTP/1.1] [Accept] = [*/*] products-expertise/renal-failure-treatments/acute-therapies-overview iw/config/asset-list.xml iw/config/asset-list.xsl